Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Inventory (2016 - 2025)

Ocular Therapeutix has reported Inventory over the past 12 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Inventory at $3.6 million for Q4 2025, up 17.24% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (up 17.24% YoY), and the annual figure for FY2025 was $3.6 million, up 17.24%.
  • Inventory for Q4 2025 was $3.6 million at Ocular Therapeutix, up from $3.5 million in the prior quarter.
  • Over the last five years, Inventory for OCUL hit a ceiling of $3.6 million in Q4 2025 and a floor of $1.1 million in Q2 2021.
  • Median Inventory over the past 5 years was $2.3 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Inventory: grew 1.45% in 2021 and later surged 66.86% in 2023.
  • Ocular Therapeutix's Inventory stood at $1.2 million in 2021, then skyrocketed by 57.92% to $2.0 million in 2022, then grew by 16.77% to $2.3 million in 2023, then skyrocketed by 31.89% to $3.0 million in 2024, then increased by 17.24% to $3.6 million in 2025.
  • The last three reported values for Inventory were $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.